Clinical trial · Interventional
Circulating Tumor Cells in Lung Cancer
Circulating Tumor Cells Identification in Advanced Stage Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): unavailability of the investigator due to an overloaded planning
Summary
Brief summary (as posted)
TITLE : Circulating tumor cells identification in advanced stage non-small cell lung cancer (CIRCUBRONCH) BACKGROUND : Circulating tumor cells identification is a new field of research in oncology, and some studies have been conducted with success on breast and prostate cancer. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV). Circulating tumor cells identification and monitoring these cells after treatment could help the clinicians to detect relapse or be a prognostic factor. PRIMARY OBJECTIVE : Circulating tumor cells identification, and monitoring in advanced stage lung cancers (IIIB and IV). SECONDARY OBJECTIVES : Predictive value of the monitoring of circulating tumor cells on the therapeutic response. Prognostic value of identification of circulating tumor cells at the time of diagnosis. STUDY DESIGN : This study is a prospective, monocentrique trial analyzing the identification of circulating tumor cells in stage IIIB, and IV non-small cell lung cancers. Duration of the inclusions: 54 months. Duration of the study: 66 months. PROCEDURES : Detection of circulating tumor cells with CellSearch system (Veridex), and a cut-off of 5 cells/7,5 ml of blood. SAMPLE SIZE : 200 patients STATISTICAL ANALYSIS : Detection of circulating tumor cells is predicted in 20% of stage IIIB, and IV non-small cell lung cancers included in this study. The cut-off is 5 circulating tumor cells per 7,5 ml of blood.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IIIB Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Stage IV Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- specific procedure
- description
- Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
- interventionNames
- Other: blood samples
Primary outcomes (1)
- measure
- Identification of circulating tumor cells in locally advanced, and metastatic non-small cell lung cancer.
- timeFrame
- 18 months
- description
- Circulating tumor cells will be search with the Veridex method, and a value per 7.5 f blood will be recorded.
Secondary outcomes (1)
- measure
- Identification of a cellular profile according to clinical factors (sex,histology, …).
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Advanced stage NSCLC (stages IIIB, and IV) with measurable or evaluable disease at diagnosis. * Age ≥ 18 years. * Measurable or evaluable disease according to RECIST criteria. * Ability to sign informed consent. Exclusion Criteria: * Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers. * Prior chemotherapy, radiation or surgery for lung cancer. * Inability to comply with study and/or follow-up procedures.
References
Publications (0)
Data not yet available